In Vivo Electrophysiological Characterization of 5-HT Receptors in the Guinea Pig Head of Caudate Nucleus and Orbitofrontal Cortex

The aim of the present study was to characterize in vivo the 5-HT receptor subtypes which mediate the effect of microiontophoretic applied 5-HT in the guinea pig head of caudate nucleus and orbitofrontal cortex. 5-HT and the preferential 5-HT2A receptor agonist DOI and the preferential 5-HT2C receptor agonist mCPP, suppressed the quisqualate (QUIS)-induced activation of neurons in both structures. The inhibitory effect of DOI and mCPP was not prevented by acute intravenous administration of the 5-HT1/2 receptor antagonist metergoline (2 mg/kg) and the 5-HT2A/2C receptor antagonist ritanserin (2 mg/kg) in the two regions nor by the selective 5-HT2A receptor antagonist MDL100907 (1 mg/kg) in the head of caudate nucleus. However, the inhibitory effect of DOI, but not that of mCPP, was antagonized by a 4-day treatment with metergoline and ritanserin (2 mg/kg/day; using minipumps implanted subcutaneously) in head of caudate nucleus, but not in orbitofrontal cortex. Microiontophoretic ejection of the 5-HT1A/7 receptor agonist 8-OH-DPAT and of the 5-HT1A receptor antagonist WAY100635 both suppressed the spontaneous and QUIS-activated firing activity of orbitofrontal cortex neurons. At current which did not affect the basal discharge activity of the neuron recorded, microiontophoretic application of WAY100635 and BMY7378 failed to prevent the inhibitory effect of 8-OH-DPAT. The inhibitory effect of gepirone, which is a 5-HT1A receptor agonist but devoid of affinity for 5-HT7 receptors, was also not antagonized by WAY100635. Altogether, these results suggest the presence of atypical 5-HT1A receptors in the orbitofrontal cortex. The present results also indicate that the suppressant effect of DOI may be mediated by 5-HT2A receptors in head of caudate nucleus and atypical 5-HT2 receptors in orbitofrontal cortex.

[1]  P. Blier,et al.  Modulation of 5‐HT release in the guinea‐pig brain following long‐term administration of antidepressant drugs , 1994, British journal of pharmacology.

[2]  G. Aghajanian,et al.  Inhibition of neurons in the amygdala by dorsal raphe stimulation: Mediation through a direct serotonergic pathway , 1977, Brain Research.

[3]  T. Insel,et al.  Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology , 1987, Biological Psychiatry.

[4]  A. Beaudet,et al.  Organization of ascending serotonin systems in the adult rat brain. A radioautographic study after intraventricular administration of [3h]5-hydroxytryptamine , 1981, Neuroscience.

[5]  D. Murphy,et al.  Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists. , 1992, European journal of pharmacology.

[6]  Y. Minabe,et al.  5-HT3-like receptors in the rat medial prefrontal cortex: an electrophysiological study , 1991, Brain Research.

[7]  C. de Montigny,et al.  Effects of the 5-hydroxytryptamine receptor antagonist, BMY 7378, on 5-hydroxytryptamine neurotransmission: electrophysiological studies in the rat central nervous system. , 1988, The Journal of pharmacology and experimental therapeutics.

[8]  D. Murphy,et al.  Effects of various serotonin receptor subtype-selective antagonists alone and on m-chlorophenylpiperazine-induced neuroendocrine changes in rats. , 1992, The Journal of pharmacology and experimental therapeutics.

[9]  T. Insel,et al.  Toward a neuroanatomy of obsessive-compulsive disorder. , 1992, Archives of general psychiatry.

[10]  J. Palacios,et al.  5-HT1D receptors in the guinea pig brain: pre- and postsynaptic localizations in the striatonigral pathway , 1990, Brain Research.

[11]  Yufei Wang,et al.  Effects of 5‐HT and 5‐HT1A receptor agonists and antagonists on dorsal vagal preganglionic neurones in anaesthetized rats: an ionophoretic study , 1995, British journal of pharmacology.

[12]  G. Aghajanian,et al.  Effects of ketanserin on neuronal responses to serotonin in the prefrontal cortex, lateral geniculate and dorsal raphe nucleus , 1985, Neuropharmacology.

[13]  J. Palacios,et al.  Localization of 5-HT1B, 5-HT1Dα, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain , 1994, Neuropharmacology.

[14]  C. de Montigny,et al.  Electrophysiological assessment of putative antagonists of 5-hydroxytryptamine receptors: a single-cell study in the rat dorsal raphe nucleus. , 1989, Canadian journal of physiology and pharmacology.

[15]  M. Segal.  5-HT antagonists in rat hippocampus , 1976, Brain Research.

[16]  E. Hollander,et al.  Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. , 1992, Archives of general psychiatry.

[17]  J. Leysen,et al.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. , 1985, Molecular pharmacology.

[18]  R. Kasser,et al.  Electrophysiological characterization of 5-hydroxytryptamine2 receptors in the rat medial prefrontal cortex. , 1990, The Journal of pharmacology and experimental therapeutics.

[19]  H. V. Van Tol,et al.  Cloning, functional expression, and mRNA tissue distribution of the rat 5-hydroxytryptamine1A receptor gene. , 1990, The Journal of biological chemistry.

[20]  M. Erlander,et al.  A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms , 1993, Neuron.

[21]  T. Insel,et al.  Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action. , 1989, Archives of general psychiatry.

[22]  S. Montgomery,et al.  Fluvoxamine in the treatment of obsessive compulsive disorder , 1992, International clinical psychopharmacology.

[23]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[24]  P. Bickford,et al.  In vivo electrochemical measurements and electrophysiological studies of rat striatum following neonatal 6-hydroxydopamine treatment , 1993, Neuroscience.

[25]  L. Descarries,et al.  Hypersensitivity to serotonin and its agonists in serotonin-hyperinnervated neostriatum after neonatal dopamine denervation. , 1994, European journal of pharmacology.

[26]  G. Kennett,et al.  m-CPP: a tool for studying behavioural responses associated with 5-HT1c receptors. , 1990, Trends in pharmacological sciences.

[27]  J. Mazziotta,et al.  Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. , 1987, Archives of general psychiatry.

[28]  A. Megens,et al.  Pharmacological profile of ritanserin: A very specific central serotonin S2‐antagonist , 1988 .

[29]  P. Blier,et al.  Functional characterization of 5‐HT1D autoreceptors on the modulation of 5‐HT release in guinea‐pig mesencephalic raphe, hippocampus and frontal cortex , 1996, British journal of pharmacology.

[30]  R. Godbout,et al.  The novel 5-HT2 receptor antagonist, RP 62203, selectively blocks serotoninergic but not dopaminergic-induced inhibition in the rat prefrontal cortex. , 1991, European journal of pharmacology.

[31]  M. Piercey,et al.  Electrophysiological evidence that spiperone is an antagonist of 5-HT1A receptors in the dorsal raphe nucleus. , 1988, European journal of pharmacology.

[32]  S. Woods,et al.  Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. , 1988, Archives of general psychiatry.

[33]  T. J. Luparello.  Stereotaxic atlas of the forebrain of the guinea pig = Stereotaktischer Atlas des Vorderhirns des Meerschweinchens = Atlas stéréotaxique du cerveau antérieur du cobaye = Atlas estereotáxico del cerebro anterior del cobaya , 1967 .

[34]  M. Titeler,et al.  Postsynaptic localization and up-regulation of serotonin 5-HT1D receptors in rat brain , 1989, Brain Research.

[35]  J. Mazziotta,et al.  Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. , 1992, Archives of general psychiatry.

[36]  P. Blier,et al.  Alteration of Serotonin Release in the Guinea Pig Orbito-Frontal Cortex by Selective Serotonin Reuptake Inhibitors , 1995, Neuropsychopharmacology.

[37]  A. Sleight,et al.  Effects of the 5-HT1D receptor antagonist GR127935 on extracellular levels of 5-HT in the guinea-pig frontal cortex as measured by microdialysis , 1995, Neuropharmacology.

[38]  E. Smeraldi,et al.  5HT‐2 receptor and fluvoxamine effect in obsessive‐compulsive disorder , 1992 .

[39]  N. Alpert,et al.  Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. , 1994, Archives of general psychiatry.

[40]  S. J. Starkey,et al.  5-HT1D as well as 5-HT1A autoreceptors modulate 5-HT release in the guinea-pig dorsal raphénucleus , 1994, Neuropharmacology.

[41]  M. Hamon,et al.  Autoradiography of serotonin receptor subtypes in the central nervous system , 1991, Neurochemistry International.

[42]  P. Blier,et al.  Pre‐ and post‐synaptic effects of the 5‐HT3 agonist 2‐Methyl‐5‐HT on the 5‐HT system in the rat brain , 1995, Synapse.

[43]  Allan Fletcher,et al.  Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist , 1995, Behavioural Brain Research.

[44]  C. de Montigny,et al.  Differential properties of pre- and postsynaptic 5-hydroxytryptamine1A receptors in the dorsal raphe and hippocampus: I. Effect of spiperone. , 1993, The Journal of pharmacology and experimental therapeutics.

[45]  C. Marsden,et al.  Withdrawal from chronic treatment with metergoline, dl-propranolol and amitriptyline enhances serotonin receptor mediated behaviour in the rat. , 1982, European journal of pharmacology.

[46]  W. Goodman,et al.  Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. , 1989, Archives of general psychiatry.

[47]  D. Murphy,et al.  Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine. , 1990, Archives of general psychiatry.

[48]  S. Maayani,et al.  Lack of 5-hydroxytryptamine1A-mediated inhibition of adenylyl cyclase in dorsal raphe of male and female rats. , 1996, The Journal of pharmacology and experimental therapeutics.

[49]  M. Hamon,et al.  Autoradiographic evidence for the heterogeneity of 5-HT1 sites in the rat brain , 1984, Brain Research.

[50]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[51]  M. Hamon,et al.  Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[52]  P Pietrini,et al.  Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. , 1992, Archives of general psychiatry.

[53]  M. Raiteri,et al.  Serotonin-glutamate interaction in rat cerebellum: involvement of 5-HT1 and 5-HT2 receptors. , 1988, European journal of pharmacology.